The recent worldwide spreading of pneumonia-causing virus, such as Coronavirus, COVID-19, and H1N1, has been endangering the life of human beings all around the world. To provide useful clues for developing antiviral ...The recent worldwide spreading of pneumonia-causing virus, such as Coronavirus, COVID-19, and H1N1, has been endangering the life of human beings all around the world. To provide useful clues for developing antiviral drugs, information of anatomical therapeutic chemicals is vitally important. In view of this, a CNN based predictor called “iATC_Deep-mISF” has been developed. The predictor is particularly useful in dealing with the multi-label systems in which some chemicals may occur in two or more different classes. To maximize the convenience for most experimental scientists, a user-friendly web-server for the new predictor has been established at http://www.jci-bioinfo.cn/iATC_Deep-mISF/, which will become a very powerful tool for developing effective drugs to fight pandemic coronavirus and save the mankind of this planet.展开更多
Abstract AIM:To evaluate the role of multi-detector row computed tomography(MDCT) angiography for assessing the therapeutic effects of percutaneous transhepatic variceal embolization(PTVE) for esophageal varices(EVs)....Abstract AIM:To evaluate the role of multi-detector row computed tomography(MDCT) angiography for assessing the therapeutic effects of percutaneous transhepatic variceal embolization(PTVE) for esophageal varices(EVs).METHODS:The subjects of this prospective study were 156 patients who underwent PTVE with cyanoacrylate for EVs.Patients were divided into three groups according to the filling range of cyanoacrylate in EVs and their feeding vessels:(1) group A,complete obliteration,with at least 3 cm of the lower EVs and peri-/EVs,as well as the adventitial plexus of the gastric cardia and fundus filled with cyanoacrylate;(2) group B,partial obliteration of varices surrounding the gastric cardia and fundus,with their feeding vessels being obliterated with cyanoacrylate,but without reaching lower EVs;and(3) group C,trunk obliteration,with the main branch of the left gastric vein being filled with cyanoacrylate,but without reaching varices surrounding the gastric cardia or fundus.We performed chart reviews and a prospective follow-up using MDCT images,angiography,and gastrointestinal endoscopy.RESULTS:The median follow-up period was 34 mo.The rate of eradication of varices for all patients was 56.4%(88/156) and the rate of relapse was 31.3%(41/131).The rates of variceal eradication at 1,3,and 5 years after PTVE were 90.2%,84.1% and 81.7%,respectively,for the complete group;61.2%,49% and 42.9%,respectively,for the partial group;with no varices disappearing in the trunk group.The relapsefree rates at 1,3 and 5 years after PTVE were 91.5%,86.6% and 81.7%,respectively,for the complete group;71.1%,55.6% and 51.1%,respectively,for the partial group;and all EVs recurred in the trunk group.Kaplan-Meier analysis showed P values of 0.000 and 0.000,and odds ratios of 3.824 and 3.603 for the rates of variceal eradication and relapse free rates,respectively.Cyanoacrylate in EVs disappeared with time,but those in the EVs and other feeding vessels remained permanently in the vessels without a decrease with time,which is important for the continued obliteration of the feeding vessels and prevention of EV relapse.CONCLUSION:MDCT provides excellent visualization of cyanoacrylate obliteration in EV and their feeding veins after PTVE.It confirms that PTVE is effective for treating EVs.展开更多
Objective:To explore the value of angiographic diagnosis and interventional therapy of the coronary artery fine branch fistula.Methods:All of the 18 patients with coronary artery fine branch fistula underwent selectiv...Objective:To explore the value of angiographic diagnosis and interventional therapy of the coronary artery fine branch fistula.Methods:All of the 18 patients with coronary artery fine branch fistula underwent selective coronary arteriography,7 underwent interventional therapy, while 8 underwent prosthesis for coronary artery fistula (CAF) under extracorpored circulation. Results:Among 18 cases of coronary artery fine branch fistula, 7 happened in right coronary artery (38.9%), 11 in left coronary artery (61.1%). Among the 11 cases in left coronary artery,5 happened in descending anterior branch, 5 occurred in left circumflex branch, 1 arised from both left anterior branch and left circumflex branch. Among the 18 cases, there are 10 cases of coronary-to-pulmonary artery fistula (55.6%), 5 cases of fistula draining into right atrium (27.8%), 2 cases of fistula draining into left atrium (11.1%) and 1 draining into right ventricle (5.6%). Interventional treatment was successful in 7 patients. During the 12 months’ follow-up, there was no cardiovascular events. Conclusion:Selective coronary angiography is the first choice for diagnosing the coronary artery fine branch fistula. In respect of therapy, besides of surgical treatment, intervention is still a rather good measure presently.展开更多
From the approval of COVID-19 mRNA vaccines to the 2023 Nobel Prize awarded for nucleoside base modifications,RNA therapeutics have entered the spotlight and are transforming drug development.While the term“RNA thera...From the approval of COVID-19 mRNA vaccines to the 2023 Nobel Prize awarded for nucleoside base modifications,RNA therapeutics have entered the spotlight and are transforming drug development.While the term“RNA therapeutics”has been used in various contexts,this review focuses on treatments that utilize RNA as a component or target RNA for therapeutic effects.We summarize the latest advances in RNA-targeting tools and RNA-based technologies,including but not limited to mRNA,antisense oligos,siRNAs,small molecules and RNA editors.We focus on the mechanisms of current FDA-approved therapeutics but also provide a discussion on the upcoming workforces.The clinical utility of RNA-based therapeutics is enabled not only by the advances in RNA technologies but in conjunction with the significant improvements in chemical modifications and delivery platforms,which are also briefly discussed in the review.We summarize the latest RNA therapeutics based on their mechanisms and therapeutic effects,which include expressing proteins for vaccination and protein replacement therapies,degrading deleterious RNA,modulating transcription and translation efficiency,targeting noncoding RNAs,binding and modulating protein activity and editing RNA sequences and modifications.This review emphasizes the concept of an RNA therapeutic toolbox,pinpointing the readers to all the tools available for their desired research and clinical goals.As the field advances,the catalog of RNA therapeutic tools continues to grow,further allowing researchers to combine appropriate RNA technologies with suitable chemical modifications and delivery platforms to develop therapeutics tailored to their specific clinical challenges.展开更多
All cells release extracellular vesicles(EVs)as part of their normal physiology.As one of the subtypes,exosomes(EXOs)have an average size range of approximately 40 nm e160 nm in diameter.Benefiting from their inherent...All cells release extracellular vesicles(EVs)as part of their normal physiology.As one of the subtypes,exosomes(EXOs)have an average size range of approximately 40 nm e160 nm in diameter.Benefiting from their inherent immunogenicity and biocompatibility,the utility of autologous EXOs has the potential for both disease diagnosis/treatment.EXOs are generally employed as“bioscaffolds”and the whole diagnostic and therapeutic effects are mainly ascribed to exogenous cargos on the EXOs,such as proteins,nucleic acids,and chemotherapeutic agents and fluorophores delivered into specific cells or tissues.Surface en-gineering of EXOs for cargo loadings is one of the prerequisites for EXO-mediated diagnosis/treatment.After revisiting EXO-mediated diagnosis/treatment,the most popular strategies to directly undertake loadings of exogenous cargos on EXOs include genetic and chemical en-gineering.Generally,genetically-engineered EXOs can be merely produced by living organisms and intrinsically face some drawbacks.However,chemical methodologies for engineered EXOs diversify cargos and extend the functions of EXOs in the diagnosis/treatment.In this review,we would like to elucidate different chemical advances on the molecular level of EXOs along with the critical design required for diagnosis/treatment.Besides,the prospects of chemical engineering on the EXOs were critically addressed.Nevertheless,the superiority of EXO-medi-ated diagnosis/treatment via chemical engineering remains a challenge in clinical translation and trials.Furthermore,more chemical crosslinking on the EXOs is expected to be explored.Despite substantial claims in the literature,there is currently no review to exclusively summa-rize the chemical engineering to EXOs for diagnosis/treatment.We envision chemical engi-neering of EXOs will encourage more scientists to explore more novel technologies for a wider range of biomedical applications and accelerate the successful translation of EXO-based drug“bioscaffolds”from bench to bedside.展开更多
Alcoholic liver disease(ALD)encompasses a range of conditions resulting from prolonged and excessive alcohol consumption,causing liver damage such as alcoholic fatty liver,inflammation,fibrosis,and cirrhosis.Alcohol c...Alcoholic liver disease(ALD)encompasses a range of conditions resulting from prolonged and excessive alcohol consumption,causing liver damage such as alcoholic fatty liver,inflammation,fibrosis,and cirrhosis.Alcohol consumption contributes to millions of deaths each year.So far,the effective treatments for ALD are limited.To date,the most effective treatment for ALD is still prevention by avoiding excessive alcohol consumption,and only few specialized medicines are in the market for the treatment of patients suffering from ALD.Small molecules targeting various pathways implicated in ALD pathogenesis can potentially be used for effective therapeutics development.In this review,we provide a concise overview of the latest research findings on potential therapeutic targets,specifically emphasizing small-molecule interventions for the treatment and prevention of ALD.展开更多
AIM: Clinical application and potential complication of percutaneous transsplenic varices embolization (PTSVE) of esophageal or gastrio-fundal varices in patients with hepatocellular carcinoma (HCC) complicated with p...AIM: Clinical application and potential complication of percutaneous transsplenic varices embolization (PTSVE) of esophageal or gastrio-fundal varices in patients with hepatocellular carcinoma (HCC) complicated with portal vein cancerous thrombosis (PVCT).METHODS: 18 patients with HCC complicated with PVCT and esophageal or gastrio-fundal varices who underwent PTSVE were collected. The rate of success, complication, mortality of the procedure and postoperative complication were recorded and analyzed.RESULTS: PTSVE were successfully performed in 16 of 18cases, and the rate of success was 89%. After therapy erythrocyte counts decreased in all of the natunts. 5 of patients needed blood transfusion, 2 patients requiredsurgical intervention because of and 11 patients with ascites were alleviated by diuresis. Among these 18patients, the procedure-related mortality was 11% (2/18),one died of acute hepatic failure on the forth day after procedure, another died of acute renal failure on the fifth day. The patients were follow up for 112 mon exceptone. 13of them died of their tumors but none of them experienced variceal bleeding.CONCLUSION: PTSVE is a relatively safe and effective method to treat esophageal or gastrio-fundal varices in HCCpatients with PVCT when percutaneous transhepatic varices embolization (PTHVE) of varices is impossible.展开更多
文摘The recent worldwide spreading of pneumonia-causing virus, such as Coronavirus, COVID-19, and H1N1, has been endangering the life of human beings all around the world. To provide useful clues for developing antiviral drugs, information of anatomical therapeutic chemicals is vitally important. In view of this, a CNN based predictor called “iATC_Deep-mISF” has been developed. The predictor is particularly useful in dealing with the multi-label systems in which some chemicals may occur in two or more different classes. To maximize the convenience for most experimental scientists, a user-friendly web-server for the new predictor has been established at http://www.jci-bioinfo.cn/iATC_Deep-mISF/, which will become a very powerful tool for developing effective drugs to fight pandemic coronavirus and save the mankind of this planet.
文摘Abstract AIM:To evaluate the role of multi-detector row computed tomography(MDCT) angiography for assessing the therapeutic effects of percutaneous transhepatic variceal embolization(PTVE) for esophageal varices(EVs).METHODS:The subjects of this prospective study were 156 patients who underwent PTVE with cyanoacrylate for EVs.Patients were divided into three groups according to the filling range of cyanoacrylate in EVs and their feeding vessels:(1) group A,complete obliteration,with at least 3 cm of the lower EVs and peri-/EVs,as well as the adventitial plexus of the gastric cardia and fundus filled with cyanoacrylate;(2) group B,partial obliteration of varices surrounding the gastric cardia and fundus,with their feeding vessels being obliterated with cyanoacrylate,but without reaching lower EVs;and(3) group C,trunk obliteration,with the main branch of the left gastric vein being filled with cyanoacrylate,but without reaching varices surrounding the gastric cardia or fundus.We performed chart reviews and a prospective follow-up using MDCT images,angiography,and gastrointestinal endoscopy.RESULTS:The median follow-up period was 34 mo.The rate of eradication of varices for all patients was 56.4%(88/156) and the rate of relapse was 31.3%(41/131).The rates of variceal eradication at 1,3,and 5 years after PTVE were 90.2%,84.1% and 81.7%,respectively,for the complete group;61.2%,49% and 42.9%,respectively,for the partial group;with no varices disappearing in the trunk group.The relapsefree rates at 1,3 and 5 years after PTVE were 91.5%,86.6% and 81.7%,respectively,for the complete group;71.1%,55.6% and 51.1%,respectively,for the partial group;and all EVs recurred in the trunk group.Kaplan-Meier analysis showed P values of 0.000 and 0.000,and odds ratios of 3.824 and 3.603 for the rates of variceal eradication and relapse free rates,respectively.Cyanoacrylate in EVs disappeared with time,but those in the EVs and other feeding vessels remained permanently in the vessels without a decrease with time,which is important for the continued obliteration of the feeding vessels and prevention of EV relapse.CONCLUSION:MDCT provides excellent visualization of cyanoacrylate obliteration in EV and their feeding veins after PTVE.It confirms that PTVE is effective for treating EVs.
文摘Objective:To explore the value of angiographic diagnosis and interventional therapy of the coronary artery fine branch fistula.Methods:All of the 18 patients with coronary artery fine branch fistula underwent selective coronary arteriography,7 underwent interventional therapy, while 8 underwent prosthesis for coronary artery fistula (CAF) under extracorpored circulation. Results:Among 18 cases of coronary artery fine branch fistula, 7 happened in right coronary artery (38.9%), 11 in left coronary artery (61.1%). Among the 11 cases in left coronary artery,5 happened in descending anterior branch, 5 occurred in left circumflex branch, 1 arised from both left anterior branch and left circumflex branch. Among the 18 cases, there are 10 cases of coronary-to-pulmonary artery fistula (55.6%), 5 cases of fistula draining into right atrium (27.8%), 2 cases of fistula draining into left atrium (11.1%) and 1 draining into right ventricle (5.6%). Interventional treatment was successful in 7 patients. During the 12 months’ follow-up, there was no cardiovascular events. Conclusion:Selective coronary angiography is the first choice for diagnosing the coronary artery fine branch fistula. In respect of therapy, besides of surgical treatment, intervention is still a rather good measure presently.
基金supported by the Terry Fox New Frontiers Program Project Grant(PPG19-1019 and 23-1124 to H.H.H).H.H.H.holds Tier 1 Canada Research Chair in RNA Medicine.M.T.is supported by the Canadian Institutes of Health Research(CIHR)Doctoral Fellowship for graduate students。
文摘From the approval of COVID-19 mRNA vaccines to the 2023 Nobel Prize awarded for nucleoside base modifications,RNA therapeutics have entered the spotlight and are transforming drug development.While the term“RNA therapeutics”has been used in various contexts,this review focuses on treatments that utilize RNA as a component or target RNA for therapeutic effects.We summarize the latest advances in RNA-targeting tools and RNA-based technologies,including but not limited to mRNA,antisense oligos,siRNAs,small molecules and RNA editors.We focus on the mechanisms of current FDA-approved therapeutics but also provide a discussion on the upcoming workforces.The clinical utility of RNA-based therapeutics is enabled not only by the advances in RNA technologies but in conjunction with the significant improvements in chemical modifications and delivery platforms,which are also briefly discussed in the review.We summarize the latest RNA therapeutics based on their mechanisms and therapeutic effects,which include expressing proteins for vaccination and protein replacement therapies,degrading deleterious RNA,modulating transcription and translation efficiency,targeting noncoding RNAs,binding and modulating protein activity and editing RNA sequences and modifications.This review emphasizes the concept of an RNA therapeutic toolbox,pinpointing the readers to all the tools available for their desired research and clinical goals.As the field advances,the catalog of RNA therapeutic tools continues to grow,further allowing researchers to combine appropriate RNA technologies with suitable chemical modifications and delivery platforms to develop therapeutics tailored to their specific clinical challenges.
基金supported by the National Natural Science Foundation of China(No.81972023)the Natural Science Foundation of Chongqing City,China(No.cstc2021jcyj-msxm0172)+2 种基金the Science and Technology Research Program of Chongqing Education Commission of China(No.KJQN201900425)Creative Research Group of CQ University(China)(No.CXQT21017)the Program for Youth Innovation in Future Medicine from Chongqing Medical University(China).
文摘All cells release extracellular vesicles(EVs)as part of their normal physiology.As one of the subtypes,exosomes(EXOs)have an average size range of approximately 40 nm e160 nm in diameter.Benefiting from their inherent immunogenicity and biocompatibility,the utility of autologous EXOs has the potential for both disease diagnosis/treatment.EXOs are generally employed as“bioscaffolds”and the whole diagnostic and therapeutic effects are mainly ascribed to exogenous cargos on the EXOs,such as proteins,nucleic acids,and chemotherapeutic agents and fluorophores delivered into specific cells or tissues.Surface en-gineering of EXOs for cargo loadings is one of the prerequisites for EXO-mediated diagnosis/treatment.After revisiting EXO-mediated diagnosis/treatment,the most popular strategies to directly undertake loadings of exogenous cargos on EXOs include genetic and chemical en-gineering.Generally,genetically-engineered EXOs can be merely produced by living organisms and intrinsically face some drawbacks.However,chemical methodologies for engineered EXOs diversify cargos and extend the functions of EXOs in the diagnosis/treatment.In this review,we would like to elucidate different chemical advances on the molecular level of EXOs along with the critical design required for diagnosis/treatment.Besides,the prospects of chemical engineering on the EXOs were critically addressed.Nevertheless,the superiority of EXO-medi-ated diagnosis/treatment via chemical engineering remains a challenge in clinical translation and trials.Furthermore,more chemical crosslinking on the EXOs is expected to be explored.Despite substantial claims in the literature,there is currently no review to exclusively summa-rize the chemical engineering to EXOs for diagnosis/treatment.We envision chemical engi-neering of EXOs will encourage more scientists to explore more novel technologies for a wider range of biomedical applications and accelerate the successful translation of EXO-based drug“bioscaffolds”from bench to bedside.
基金supported by the National Institute of Diabetes and Digestive and Kidney(R01-DK121970)to Dr.Feng Li.
文摘Alcoholic liver disease(ALD)encompasses a range of conditions resulting from prolonged and excessive alcohol consumption,causing liver damage such as alcoholic fatty liver,inflammation,fibrosis,and cirrhosis.Alcohol consumption contributes to millions of deaths each year.So far,the effective treatments for ALD are limited.To date,the most effective treatment for ALD is still prevention by avoiding excessive alcohol consumption,and only few specialized medicines are in the market for the treatment of patients suffering from ALD.Small molecules targeting various pathways implicated in ALD pathogenesis can potentially be used for effective therapeutics development.In this review,we provide a concise overview of the latest research findings on potential therapeutic targets,specifically emphasizing small-molecule interventions for the treatment and prevention of ALD.
基金Supported by tackling key pnoblems in science and technology from the State Science and Technology Minisity,TJ99-LA01,No.96-907-03-01
文摘AIM: Clinical application and potential complication of percutaneous transsplenic varices embolization (PTSVE) of esophageal or gastrio-fundal varices in patients with hepatocellular carcinoma (HCC) complicated with portal vein cancerous thrombosis (PVCT).METHODS: 18 patients with HCC complicated with PVCT and esophageal or gastrio-fundal varices who underwent PTSVE were collected. The rate of success, complication, mortality of the procedure and postoperative complication were recorded and analyzed.RESULTS: PTSVE were successfully performed in 16 of 18cases, and the rate of success was 89%. After therapy erythrocyte counts decreased in all of the natunts. 5 of patients needed blood transfusion, 2 patients requiredsurgical intervention because of and 11 patients with ascites were alleviated by diuresis. Among these 18patients, the procedure-related mortality was 11% (2/18),one died of acute hepatic failure on the forth day after procedure, another died of acute renal failure on the fifth day. The patients were follow up for 112 mon exceptone. 13of them died of their tumors but none of them experienced variceal bleeding.CONCLUSION: PTSVE is a relatively safe and effective method to treat esophageal or gastrio-fundal varices in HCCpatients with PVCT when percutaneous transhepatic varices embolization (PTHVE) of varices is impossible.
